210 related articles for article (PubMed ID: 14512129)
1. A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers.
Martin PD; Warwick MJ; Dane AL; Cantarini MV
Clin Ther; 2003 Aug; 25(8):2215-24. PubMed ID: 14512129
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study.
Li Y; Jiang X; Lan K; Zhang R; Li X; Jiang Q
Clin Ther; 2007 Oct; 29(10):2194-203. PubMed ID: 18042475
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of rosuvastatin in healthy Chinese volunteers living in China: a randomized, open-label, ascending single- and multiple-dose study.
Li XN; Xu HR; Chen WL; Chu NN; Zhu JR
Clin Ther; 2010 Mar; 32(3):575-87. PubMed ID: 20399994
[TBL] [Abstract][Full Text] [Related]
4. Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers.
Martin PD; Warwick MJ; Dane AL; Brindley C; Short T
Clin Ther; 2003 Oct; 25(10):2553-63. PubMed ID: 14667956
[TBL] [Abstract][Full Text] [Related]
5. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers.
Martin PD; Warwick MJ; Dane AL; Hill SJ; Giles PB; Phillips PJ; Lenz E
Clin Ther; 2003 Nov; 25(11):2822-35. PubMed ID: 14693307
[TBL] [Abstract][Full Text] [Related]
6. The effect of a combination antacid preparation containing aluminium hydroxide and magnesium hydroxide on rosuvastatin pharmacokinetics.
Martin PD; Schneck DW; Dane AL; Warwick MJ
Curr Med Res Opin; 2008 Apr; 24(4):1231-5. PubMed ID: 18355422
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers.
Martin PD; Mitchell PD; Schneck DW
Br J Clin Pharmacol; 2002 Nov; 54(5):472-7. PubMed ID: 12445025
[TBL] [Abstract][Full Text] [Related]
8. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine.
Simonson SG; Raza A; Martin PD; Mitchell PD; Jarcho JA; Brown CD; Windass AS; Schneck DW
Clin Pharmacol Ther; 2004 Aug; 76(2):167-77. PubMed ID: 15289793
[TBL] [Abstract][Full Text] [Related]
9. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin.
Schneck DW; Birmingham BK; Zalikowski JA; Mitchell PD; Wang Y; Martin PD; Lasseter KC; Brown CD; Windass AS; Raza A
Clin Pharmacol Ther; 2004 May; 75(5):455-63. PubMed ID: 15116058
[TBL] [Abstract][Full Text] [Related]
10. An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers.
Martin PD; Dane AL; Schneck DW; Warwick MJ
Clin Ther; 2003 Feb; 25(2):459-71. PubMed ID: 12749507
[TBL] [Abstract][Full Text] [Related]
11. The effect of fluconazole on the pharmacokinetics of rosuvastatin.
Cooper KJ; Martin PD; Dane AL; Warwick MJ; Schneck DW; Cantarini MV
Eur J Clin Pharmacol; 2002 Nov; 58(8):527-31. PubMed ID: 12451430
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor.
Kulmatycki K; Hanna I; Meyers D; Salunke A; Movva A; Majumdar T; Natrillo A; Vapurcuyan A; Rebello S; Sunkara G; Chen J
Int J Clin Pharmacol Ther; 2015 May; 53(5):345-55. PubMed ID: 25740267
[TBL] [Abstract][Full Text] [Related]
13. Single-dose, 2-way crossover, bioequivalence study of two rosuvastatin formulations in normal healthy subjects under fasting conditions.
Trabelsi F; Bartůnek A; Vlavonou R; Navrátilová L; Dubé C; Tanguay M; Hauser T
Int J Clin Pharmacol Ther; 2012 Oct; 50(10):741-50. PubMed ID: 22762855
[TBL] [Abstract][Full Text] [Related]
14. Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males.
Zhang W; Yu BN; He YJ; Fan L; Li Q; Liu ZQ; Wang A; Liu YL; Tan ZR; Fen-Jiang ; Huang YF; Zhou HH
Clin Chim Acta; 2006 Nov; 373(1-2):99-103. PubMed ID: 16784736
[TBL] [Abstract][Full Text] [Related]
15. The effect of erythromycin on the pharmacokinetics of rosuvastatin.
Cooper KJ; Martin PD; Dane AL; Warwick MJ; Raza A; Schneck DW
Eur J Clin Pharmacol; 2003 May; 59(1):51-6. PubMed ID: 12682802
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of rosuvastatin in patients with end-stage kidney disease undergoing peritoneal dialysis.
Bologa R; Levine D; Parker T; Gordon B; Lanto A; Cheigh J; Stenzel K; Rubin A
Clin Nephrol; 2009 Dec; 72(6):437-41. PubMed ID: 19954720
[TBL] [Abstract][Full Text] [Related]
17. Effect of itraconazole on the pharmacokinetics of rosuvastatin.
Cooper KJ; Martin PD; Dane AL; Warwick MJ; Schneck DW; Cantarini MV
Clin Pharmacol Ther; 2003 Apr; 73(4):322-9. PubMed ID: 12709722
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of rosuvastatin/olmesartan fixed-dose combination: a single-dose, randomized, open-label, 2-period crossover study in healthy Korean subjects.
Son H; Roh H; Lee D; Chang H; Kim J; Yun C; Park K
Clin Ther; 2013 Jul; 35(7):915-22. PubMed ID: 23810276
[TBL] [Abstract][Full Text] [Related]
19. No effect of rosuvastatin on the pharmacokinetics of digoxin in healthy volunteers.
Martin PD; Kemp J; Dane AL; Warwick MJ; Schneck DW
J Clin Pharmacol; 2002 Dec; 42(12):1352-7. PubMed ID: 12463730
[TBL] [Abstract][Full Text] [Related]
20. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin.
Pasanen MK; Fredrikson H; Neuvonen PJ; Niemi M
Clin Pharmacol Ther; 2007 Dec; 82(6):726-33. PubMed ID: 17473846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]